CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma

Thyroid

Volumn 16, Issue 7, 2006, Pages 633-642

  Schagdarsurengin, Undraga ^a   Gimm, Oliver ^a   Dralle, Henning ^a   Hoang Vu, Cuong ^a   Dammann, Reinhard ^a,b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Institut fur Humangenetik und Medizinische Biologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; DIPEPTIDYL PEPTIDASE IV; DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE PRODUCT; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16INK4A; PROTEIN SLC5A8; PROTEIN UCHL1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CLASSIFICATION; CD26 GENE; CPG ISLAND; DAPK GENE; DEMETHYLATION; ERALPHA GENE; ERBETA GENE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GOITER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERMETHYLATION; MGMT GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; P16 GENE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; PTEN GENE; RARBETA GENE; RASSF1A GENE; SLC5A8 GENE; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TSHR GENE; UCHL1 GENE; UNDIFFERENTIATED CARCINOMA; VALIDATION PROCESS;

CARCINOMA; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; THYROID NEOPLASMS;

EID: 33747367221     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.633     Document Type: Article

References (41)

1. Mazzaferri EL 1993 Management of a solitary thyroid nodule. N Engl J Med 328:553-559.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648.
3. Correa P, Chen VW 1995 Endocrine gland cancer. Cancer 75:338-352.
4. Gimm O 2001 Thyroid cancer. Cancer Lett 163:143-156.
5. Pettersson B, Coleman MP, Ron E, Adami HO 1996 Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. Int J Cancer 65:13-19.
6. Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr DJ, MacFarlane GJ 1993 The epidemiology of thyroid carcinoma. Crit Rev Oncog 4:25-52.
7. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP 1997 Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: A retrospective analysis of 700 patients. J Clin Endocrinol Metab 82:3553-3562.
8. Sherman SI 2003 Thyroid carcinoma. Lancet 361:501-511.
9. Moretti F, Nanni S, Pontecorvi A 2000 Molecular pathogenesis of thyroid nodules and cancer. Baillieres Best Pract Res Clin Endocrinol Metab 14:517-539.
10. Herman JG, Baylin SB 2003 Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054.
11. Jones PA, Baylin SB 2002 The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428.
12. Seidel C, Bartel F, Rastetter M, Bluemke K, Wurl P, Taubert H, Dammann R 2005 Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer 114:442-447.
13. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R 2002 Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 62:3698-3701.
14. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, Sidransky D 2004 Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 64:1664-1668.
15. Elisei R, Shiohara M, Koeffler HP, Fagin JA 1998 Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4A in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 83:2185-2193.
16. Xing M, Tokumaru Y, Wu G, Westra WB, Ladenson PW, Sidransky D 2003 Hypermethylation of the Pendred syndrome gene SLC26A4 is an early event in thyroid tumorigenesis. Cancer Res 63:2312-2315.
17. Neumann S, Schuchardt K, Reske A, Emmrich P, Paschke R 2004 Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules. Thyroid 14:99-111.
18. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C, Eng C 2003 Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res 63:2864-2871.
19. Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, Tong BC, Tallini G, Udelsman R, Califano JA, Ladenson PW, Sidransky D 2003 Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: A marker of malignancy and a cause of gene silencing. Cancer Res 63:2316-2321.
20. Ogasawara S, Maesawa C, Yamamoto M, Akiyama Y, Wada K, Fujisawa K, Higuchi T, Tomisawa Y, Sato N, Fjido S, Saito K, Masuda T 2004 Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene 23:1117-1124.
21. Boltze C, Schneider-Stock R, Quednow C, Hinze R, Mawrin C, Hribaschek A, Roessner A, Hoang-Vu C 2003 Silencing of the maspin gene by promoter hypermethylation in thyroid cancer. Int J Mol Med 12:479-484.
22. Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, Zeiger MA, Sidransky D, Umbricht CB 2005 Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab 90:4011-4018.
23. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP 2000 Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25:315-319.
24. Dulgeroff AJ, Hershman JM 1994 Medical therapy for differentiated thyroid carcinoma. Endocr Rev 15:500-515.
25. Ain KB 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715-726.
26. Haugen BR 2004 Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord 4:175-180.
27. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR 2001 Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery 130:1028-1034.
28. Egger G, Liang G, Aparicio A, Jones PA 2004 Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463.
29. Claus R, Lubbert M 2003 Epigenetic targets in hematopoietic malignancies. Oncogene 22:6489-6496.
30. Lubbert M, Hasskarl J, Claus R DNA demethylating agents: clinical uses. In: M. Esteller (ed) DNA Methylation: Approaches, Methods and Applications. CRC Press, Boca Raton, 2005, pp. 183-212.
31. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R 2000 Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLHl gene promoter. Cancer Res 60:6039-6044.
32. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB 1996 Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826.
33. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM, et al. 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579.
34. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262.
35. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G 2003 ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21:3226-3235.
36. Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, Dammann R 2005 Chroma tin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol 25:3923-3933.
37. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH, Goggins M 2003 Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63:3735-3742.
38. Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C 2003 Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res 63:8500-8506.
39. Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, Willis J, Willson JK, Plass C, Markowitz SD 2003 SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA 100:8412-8417.
40. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Mutter GL, Robinson BG, Komminoth P, Dralle H, Eng C 2000 Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156:1693-1700.
41. Kawabata W, Suzuki T, Moriya T, Fujimori K, Naganuma H, Inoue S, Kinouchi Y, Kameyama K, Takami H, Shimosegawa T, Sasano H 2003 Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: Possible in situ estrogen synthesis and actions. Mod Pathol 16:437-444.